Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBSS1113 and Azacitidine in AML and MDS
NCT07761533Phase 2Recruiting
- Sponsor
- Chaser Therapeutics
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
A Phase 2 trial of CT1113 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Chaser Therapeutics. Started Sep 2025; status: recruiting.
02
Drugs
CT1113
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07761533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07761533.